These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34130563)

  • 1. Asciminib: an investigational agent for the treatment of chronic myeloid leukemia.
    Breccia M; Colafigli G; Scalzulli E; Martelli M
    Expert Opin Investig Drugs; 2021 Aug; 30(8):803-811. PubMed ID: 34130563
    [No Abstract]   [Full Text] [Related]  

  • 2. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
    Hughes TP; Mauro MJ; Cortes JE; Minami H; Rea D; DeAngelo DJ; Breccia M; Goh YT; Talpaz M; Hochhaus A; le Coutre P; Ottmann O; Heinrich MC; Steegmann JL; Deininger MWN; Janssen JJWM; Mahon FX; Minami Y; Yeung D; Ross DM; Tallman MS; Park JH; Druker BJ; Hynds D; Duan Y; Meille C; Hourcade-Potelleret F; Vanasse KG; Lang F; Kim DW
    N Engl J Med; 2019 Dec; 381(24):2315-2326. PubMed ID: 31826340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asciminib as a third line option in chronic myeloid leukemia.
    Laganà A; Scalzulli E; Carmosino I; Martelli M; Breccia M
    Int J Hematol; 2023 Jan; 117(1):16-23. PubMed ID: 35930119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
    Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
    Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
    Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
    J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asciminib: First Approval.
    Deeks ED
    Drugs; 2022 Feb; 82(2):219-226. PubMed ID: 35041175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors.
    García-Gutiérrez V; Hernandez-Boluda JC
    Expert Rev Hematol; 2022 Jun; 15(6):477-484. PubMed ID: 35583386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
    Yeung DT; Shanmuganathan N; Hughes TP
    Blood; 2022 Jun; 139(24):3474-3479. PubMed ID: 35468180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
    Wylie AA; Schoepfer J; Jahnke W; Cowan-Jacob SW; Loo A; Furet P; Marzinzik AL; Pelle X; Donovan J; Zhu W; Buonamici S; Hassan AQ; Lombardo F; Iyer V; Palmer M; Berellini G; Dodd S; Thohan S; Bitter H; Branford S; Ross DM; Hughes TP; Petruzzelli L; Vanasse KG; Warmuth M; Hofmann F; Keen NJ; Sellers WR
    Nature; 2017 Mar; 543(7647):733-737. PubMed ID: 28329763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
    Réa D; Hughes TP
    Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.
    Oruganti B; Lindahl E; Yang J; Amiri W; Rahimullah R; Friedman R
    J Biol Chem; 2022 Aug; 298(8):102238. PubMed ID: 35809644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asciminib in chronic myeloid leukemia.
    Assanto GM; Scalzulli E; Breccia M
    Drugs Today (Barc); 2022 Oct; 58(10):479-489. PubMed ID: 36305542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
    Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
    Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
    Manley PW; Barys L; Cowan-Jacob SW
    Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia.
    Yoshida C; Takaku T
    Med; 2024 Aug; 5(8):856-858. PubMed ID: 39127034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib.
    G Lindström HJ; Friedman R
    BMC Cancer; 2020 May; 20(1):397. PubMed ID: 32380976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.
    Monestime S; Al Sagheer T; Tadros M
    Am J Health Syst Pharm; 2023 Jan; 80(2):36-43. PubMed ID: 36197958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
    Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
    Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
    Luna A; Pérez-Lamas L; Boque C; Giraldo P; Xicoy B; Ruiz Nuño C; Vega MM; Alvarez-Larrán A; Salamanca A; García-Noblejas A; Vall-Llovera F; Villalon L; De Las Heras N; Ramila E; Pérez-Encinas M; Cuevas B; Perez-Lopez R; Sanchez-Guijo F; Jiménez-Velasco A; Lakhwani S; Casado LF; Rosell A; Escola A; Fernández MJ; Garcia-Hernandez C; Cervero C; Mora E; Sagüés M; Suarez-Varela S; Vélez P; Carrascosa Mastell P; Bitaube RF; Serrano L; Cortes M; Vera Goñi JA; Steegmann JL; de Soria VGG; Alonso-Dominguez JM; Araujo MC; Coll AP; Hernandez-Boluda JC; García-Gutiérrez V
    Ann Hematol; 2022 Oct; 101(10):2263-2270. PubMed ID: 35997804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asciminib for chronic myeloid leukaemia: Next questions.
    Shanmuganathan N; Hughes TP
    Br J Haematol; 2022 Nov; 199(3):322-331. PubMed ID: 35729850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.